Lineage Cell Therapeutics (LCTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.98, -1.18% vs the prior close of $0.99.
- Volume 1.31M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
LCTX dips 1.2% to $0.98. Closed at $0.98, -1.18% vs the prior close of $0.99. Day range $0.96–$1.00, opened at $0.98.
LCTX daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — LCTX dips 1.2% to $0.98
- Closed at $0.98, -1.18% vs the prior close of $0.99. Day range $0.96–$1.00, opened at $0.98.
- Volume was 1.31M shares, 1.0x its 50-day average of 1.28M.
- Price is -5.5% vs its 50-day average ($1.03) and -28.2% vs its 200-day average ($1.36).
- 52-week range $0.88–$2.09; today's close sits at 8% of that range, 53.2% below the 52-week high.
Oct 15, 2026 — LCTX jumps 7.6% to $0.99
- Closed at $0.99, +7.61% vs the prior close of $0.92. Day range $0.92–$1.00, opened at $0.92.
- Volume was 1.42M shares, 1.1x its 50-day average of 1.26M.
- Price is -4.6% vs its 50-day average ($1.04) and -27.5% vs its 200-day average ($1.37).
- 52-week range $0.88–$2.09; today's close sits at 9% of that range, 52.6% below the 52-week high.
Oct 14, 2026 — LCTX rises 1.1% to $0.92
- Closed at $0.92, +1.10% vs the prior close of $0.91. Day range $0.89–$0.94, opened at $0.91.
- Volume was 2.20M shares, 1.8x its 50-day average of 1.23M.
- Price is -11.6% vs its 50-day average ($1.04) and -32.8% vs its 200-day average ($1.37).
- 52-week range $0.88–$2.09; today's close sits at 3% of that range, 56.0% below the 52-week high.
Oct 13, 2026 — LCTX slides 4.2% to $0.91, 3 down days in a row
- Closed at $0.91, -4.21% vs the prior close of $0.95. Day range $0.90–$0.97, opened at $0.95.
- Volume was 1.78M shares, 1.5x its 50-day average of 1.21M.
- Price is -12.9% vs its 50-day average ($1.04) and -33.7% vs its 200-day average ($1.37).
- 52-week range $0.88–$2.09; today's close sits at 2% of that range, 56.5% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — LCTX slides 4.0% to $0.95
- Closed at $0.95, -4.04% vs the prior close of $0.99. Day range $0.94–$1.00, opened at $1.00.
- Volume was 1.69M shares, 1.4x its 50-day average of 1.20M.
- Price is -9.4% vs its 50-day average ($1.05) and -31.0% vs its 200-day average ($1.38).
- 52-week range $0.88–$2.09; today's close sits at 6% of that range, 54.5% below the 52-week high.
Oct 9, 2026 — LCTX slides 3.9% to $0.99
- Closed at $0.99, -3.88% vs the prior close of $1.03. Day range $0.98–$1.03, opened at $1.02.
- Volume was 1.16M shares, 1.0x its 50-day average of 1.20M.
- Price is -5.8% vs its 50-day average ($1.05) and -28.2% vs its 200-day average ($1.38).
- 52-week range $0.88–$2.09; today's close sits at 9% of that range, 52.6% below the 52-week high.
Oct 8, 2026 — LCTX jumps 8.4% to $1.03, 3 up days in a row
- Closed at $1.03, +8.42% vs the prior close of $0.95. Day range $0.93–$1.05, opened at $0.95.
- Volume was 2.01M shares, 1.7x its 50-day average of 1.18M.
- Price is -2.3% vs its 50-day average ($1.05) and -25.5% vs its 200-day average ($1.38).
- 52-week range $0.88–$2.09; today's close sits at 12% of that range, 50.7% below the 52-week high.
- That makes 3 straight gains.
Oct 7, 2026 — LCTX rises 1.1% to $0.95
- Closed at $0.95, +1.06% vs the prior close of $0.94. Day range $0.92–$0.97, opened at $0.94.
- Volume was 1.48M shares, 1.3x its 50-day average of 1.17M.
- Price is -9.9% vs its 50-day average ($1.05) and -31.5% vs its 200-day average ($1.39).
- 52-week range $0.88–$2.09; today's close sits at 6% of that range, 54.5% below the 52-week high.
Oct 6, 2026 — LCTX rises 1.1% to $0.94
- Closed at $0.94, +1.08% vs the prior close of $0.93. Day range $0.93–$0.97, opened at $0.94.
- Volume was 966.90K shares, 0.8x its 50-day average of 1.19M.
- Price is -11.1% vs its 50-day average ($1.06) and -32.4% vs its 200-day average ($1.39).
- 52-week range $0.88–$2.09; today's close sits at 5% of that range, 55.0% below the 52-week high.
Oct 5, 2026 — LCTX ends flat (+0.0%) to $0.93
- Closed at $0.93, +0.00% vs the prior close of $0.93. Day range $0.91–$0.96, opened at $0.93.
- Volume was 1.39M shares, 1.2x its 50-day average of 1.18M.
- Price is -12.1% vs its 50-day average ($1.06) and -33.3% vs its 200-day average ($1.39).
- 52-week range $0.88–$2.09; today's close sits at 4% of that range, 55.5% below the 52-week high.
Oct 2, 2026 — LCTX jumps 3.3% to $0.93
- Closed at $0.93, +3.33% vs the prior close of $0.90. Day range $0.89–$0.96, opened at $0.92.
- Volume was 1.25M shares, 1.1x its 50-day average of 1.18M.
- Price is -12.3% vs its 50-day average ($1.06) and -33.5% vs its 200-day average ($1.40).
- 52-week range $0.88–$2.09; today's close sits at 4% of that range, 55.5% below the 52-week high.
LCTX latest news & SEC filings
Every SEC filing by or about LCTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $1.07M (prior year $2.77M) (-61.3% vs Jun 30, 2025)
- Net income: $1.48M (prior year -$30.46M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: -$0.03 (prior year -$0.13) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade LCTX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Mar 5, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.66% (largest 8.4%). That is a volatile stock.
- Liquidity: about 1.64M shares (≈$1.61M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.98 vs a range of $0.88–$2.09 (8% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Brian M Culley bought 15,000 shares on Mar 12, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 12, 2026.
- Share count: 252.91M shares outstanding (Aug 3, 2026), +10.8% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Biological Products, (No Diagnostic Substances).
LCTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.98 | 1.00 | 0.96 | 0.98 | 1.31M |
| Oct 15, 2026 | 0.92 | 1.00 | 0.92 | 0.99 | 1.42M |
| Oct 14, 2026 | 0.91 | 0.94 | 0.89 | 0.92 | 2.20M |
| Oct 13, 2026 | 0.95 | 0.97 | 0.90 | 0.91 | 1.78M |
| Oct 12, 2026 | 1.00 | 1.00 | 0.94 | 0.95 | 1.69M |
| Oct 9, 2026 | 1.02 | 1.03 | 0.98 | 0.99 | 1.16M |
| Oct 8, 2026 | 0.95 | 1.05 | 0.93 | 1.03 | 2.01M |
| Oct 7, 2026 | 0.94 | 0.97 | 0.92 | 0.95 | 1.48M |
| Oct 6, 2026 | 0.94 | 0.97 | 0.93 | 0.94 | 966.90K |
| Oct 5, 2026 | 0.93 | 0.96 | 0.91 | 0.93 | 1.39M |
| Oct 2, 2026 | 0.92 | 0.96 | 0.89 | 0.93 | 1.25M |
| Oct 1, 2026 | 0.96 | 0.97 | 0.88 | 0.90 | 1.65M |
| Sep 30, 2026 | 0.95 | 0.99 | 0.94 | 0.96 | 1.27M |
| Sep 29, 2026 | 0.98 | 0.99 | 0.92 | 0.95 | 2.59M |
| Sep 28, 2026 | 1.02 | 1.04 | 0.96 | 0.97 | 1.57M |
| Sep 25, 2026 | 0.95 | 1.04 | 0.94 | 1.03 | 2.48M |
| Sep 24, 2026 | 0.95 | 0.97 | 0.91 | 0.95 | 2.44M |
| Sep 23, 2026 | 1.02 | 1.04 | 0.96 | 0.96 | 2.63M |
| Sep 22, 2026 | 1.02 | 1.05 | 1.00 | 1.04 | 846.80K |
| Sep 21, 2026 | 1.03 | 1.05 | 1.01 | 1.01 | 720.70K |
About Lineage Cell Therapeutics
Lineage Cell Therapeutics (LCTX) is listed on the NYSE and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in CARLSBAD, CA. State of incorporation: CA. Fiscal year ends December 31. SEC CIK 876343.
LCTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Deborah J Andrews | Director | Jul 2, 2026 |
| Dipti Amin | Director | Jul 2, 2026 |
| Neal C Bradsher | Director | Jul 2, 2026 |
| Brian M Culley | President and CEO | Mar 12, 2026 |
| Anula Jayasuriya | Director | Jul 2, 2026 |
| Michael H. Mulroy | Director | Jul 2, 2026 |
| Angus C. Russell | Director | Jul 2, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Brian M Culley | President and CEO | Mar 12, 2026 |
| Jill Ann Howe | Chief Financial Officer | Mar 6, 2026 |
| George A. Iii Samuel | General Counsel and Secretary | Mar 6, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 12, 2026 | Brian M Culley | Buy | 15,000 | $1.63 |
| Mar 12, 2026 | Brian M Culley | Buy | 15,000 | $1.63 |
| Mar 12, 2026 | Brian M Culley | Buy | 15,000 | $1.63 |
| Mar 12, 2026 | Brian M Culley | Buy | 15,000 | $1.63 |
LCTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $14.56M | $-63.53M | -0.28 | $-18.92M |
| Dec 31, 2024 | $9.50M | $-18.61M | -0.09 | $-23.09M |
| Dec 31, 2023 | $8.95M | $-21.49M | -0.12 | $-28.57M |
| Dec 31, 2022 | $14.70M | $-26.27M | -0.15 | $1.06M |
| Dec 31, 2021 | $4.34M | $-43.02M | — | $-23.56M |
Latest balance sheet: total assets $106.22M, total liabilities $46.42M, cash $37.35M (as of Jun 30, 2026).
LCTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $1.13 |
| May 12, 2026 | 8-K Item 2.02 (results) | $1.33 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $1.84 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $1.73 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.01 |
| May 13, 2025 | 8-K Item 2.02 (results) | $0.47 |
| Mar 10, 2025 | 8-K Item 2.02 (results) | $0.53 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $0.89 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 7, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on LCTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.